Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease

Abstract Introduction People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Methods Noradrenaline, adrenaline, and their metabolite 3‐methoxy‐4‐hydr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Alain D. Dekker, Yannick Vermeiren, Maria Carmona‐Iragui, Bessy Benejam, Laura Videla, Ellen Gelpi, Tony Aerts, Debby Van Dam, Susana Fernández, Alberto Lleó, Sebastian Videla, Anne Sieben, Jean‐Jacques Martin, Netherlands Brain Bank, Rafael Blesa, Juan Fortea, Peter P. De Deyn
Format: Artigo
Langue:Inglês
Publié: Wiley 2018-01-01
Collection:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Sujets:
Alzheimer's disease
Cerebrospinal fluid
Dementia
Dopamine
Down syndrome
Monoamines
Accès en ligne:https://doi.org/10.1016/j.dadm.2017.11.001
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires